ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dowling, R. D.
Right arrow Articles by Armitage, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dowling, R. D.
Right arrow Articles by Armitage, J. M.

The Annals of Thoracic Surgery, Vol 56, 1176-1177, Copyright © 1993 by The Society of Thoracic Surgeons

ARTICLES

Clinical cardiopulmonary bypass without systemic anticoagulation

RD Dowling, ME Brown, RO Whittington Jr, JJ Quinlan and JM Armitage
Department of Cardiothoracic Surgery and Anesthesiology, University of Pittsburgh, PA 15216.

Heparin-coated perfusion systems have been used to perform cardiopulmonary bypass with decreased systemic heparin dosages. We report the case of a 60-year-old man with end-stage liver disease and severe aortic stenosis who underwent an aortic valve replacement without systemic anticoagulation, employing a heparin-coated perfusion system. In patients with a contraindication to systemic anticoagulation, cardiopulmonary bypass with a heparin-coated system without systemic anticoagulation may be a viable alternative.


This article has been cited by other articles:


Home page
 Ann. Thorac. Surg.Home page
J. Butler, E. W. Murithi, V. L. Pathi, K. J.D. MacArthur, and G. A. Berg
Duroflo II heparin bonding does not attenuate cytokine release or improve pulmonary function
Ann. Thorac. Surg., July 1, 2002; 74(1): 139 - 142.
[Abstract] [Full Text] [PDF]

Home page
 PerfusionHome page
C B. Mahoney
Heparin-bonded circuits: clinical outcomes and costs
Perfusion, May 1, 1998; 13(3): 192 - 204.
[Abstract] [PDF]

Home page
 PerfusionHome page
M. Yii, T. Gourlay, J. Fleming, B. Matata, and K. Taylor
Evaluation of Carmeda(R) Bioactive Surface (CBAS(R)), Duraflo II and a novel nonspecific protease-modified surface using a new in vitro model simulating cardiopulmonary bypass
Perfusion, May 1, 1996; 11(3): 229 - 240.
[PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
R. L. Korn, C. A. Fisher, E. R. Livingston, N. Stenach, S. J. Fishman, V. Jeevanandam, and V. P. Addonizio
THE EFFECTS OF CARMEDA BIOACTIVE SURFACE ON HUMAN BLOOD COMPONENTS DURING SIMULATED EXTRACORPOREAL CIRCULATION
J. Thorac. Cardiovasc. Surg., May 1, 1996; 111(5): 1073 - 1084.
[Abstract] [Full Text]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
R. C. Gorman, N. P. Ziats, A. K. Rao, N. Gikakis, L. Sun, M. M. H. Khan, N. Stenach, S. Sapatnekar, V. Chouhan, J. H. Gorman III, et al.
SURFACE-BOUND HEPARIN FAILS TO REDUCE THROMBIN FORMATION DURING CLINICAL CARDIOPULMONARY BYPASS
J. Thorac. Cardiovasc. Surg., January 1, 1996; 111(1): 1 - 12.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 1993 by The Society of Thoracic Surgeons.